Download the ASM Events mobile app now! 

2017 Clinical Virology Symposium Final Program

2017 Clinical Virology Symposium Exhibit & Poster Hall Guide 


Past Meeting Materials


Symposium Chairman

Steven Specter, PhD; Univ. of South Florida Morsani Coll. of Med., Tampa, FL

Symposium Vice-Chairman

Richard L. Hodinka, PhD; Univ. of South Carolina Sch. of Med. Greenville, Greenville, SC 

Program Committee Members


Follow #ASMCVS on Twitter for the latest updates on this meeting! 

"This meeting does an incredible job of bringing together laboratorians, IVD manufacturers and academics to survey the current state of clinical virology and indicate what the future directions are likely to be."
Mark Poritz, VP of Chemistry Research, BioFire Defense

Industry & Science Workshops

Learn more about the products and services offered by our Exhibitors by attending an Industry & Science Workshop. 

Industry & Science Workshops are sessions supported by the industry to complement the official CVS program. Industry & Science Workshops are not part of the official Clinical Virology Symposium as planned by the Program Committee. There is no fee to attend the Workshops. Seating for all workshops is limited and will be available on a first-come, first serve basis.


Featured Industry & Science Workshop

pcr.ai (formerly known as Azure PCR’s AccuCall) presents a workshop on qPCR and artificial intelligence 
Supported by pcr.ai (formerly known as Azure PCR’s AccuCall) 
Location: Westin, Grand Ballroom Salon D
Monday, May 8, 2017 - 3:00 p.m. – 4:30 p.m.



Monday, May 8, 2017 - 
1:15 p.m. – 2:45 p.m.

Performance evaluation of the Abbott RealTime CMV* assay on the m2000 platform 
Supported by Abbott Molecular 
Location: Westin, Grand Ballroom Salon C

Elevating the Standard of Care for Diagnosis and Management of Vaginitis & Vaginosi 
Supported by BD Diagnostics 
Location: Savannah International Trade & Convention Center, Room 203-205

Big Changes in Influenza Testing, Are you Ready?
Supported by Cepheid 
Location: Savannah International Trade & Convention Center, Oglethorpe Auditorium

ELITe InGenius®, the Highly Flexible Sample-to-Result Solution 
Supported by ELITechGroup Molecular Diagnostics 
Location: Westin, Grand Ballroom Salon B

Panther Fusion and a Novel Approach to Syndromic Respiratory Testing 
Supported by Hologic, Inc
Location: Westin, Grand Ballroom Salon A

Flexible Solutions from Luminex – The Right Test for Your Lab 
Supported by Luminex Corporation
Location: Westin, Grand Ballroom Salon E/F

VZV: The Great Imposter / CDC Guidelines for Influenza Testing and Impact on Algorithms
Supported by Quidel Corporation
Location: Westin, Harbor Ballroom B

The Odyssey of Disparities in Standardizing CMV Viral Load Testing:  Have the Seas Subsided? 
Supported by Roche Diagnostics
Location: Savannah International Trade & Convention Center, Room 105/106

RTT Molecular Diagnostics Workshop
Supported by RTT Molecular Diagnostics
Location: Westin, Harbor Ballroom A


Monday, May 8, 2017 - 3:00 p.m. – 4:30 p.m.

The FilmArray® Respiratory Panel 2 (RP2) Ad¬vancing the Syndromic Approach: Faster, More Accurate, More Comprehensive…Than Ever!
Supported by BioFire Diagnostics 
Location: Westin, Grand Ballroom Salon C

Lyophilizing PCR Master Mixes for Molecular Diagnostic Assays
Supported by BIOLYPH
Location: Westin, Harbor Ballroom A

Advances in Lab Detection of C. difficile and Group A Strep
Supported by DiaSorin Molecular
Location: Westin, Grand Ballroom Salon B

Implementation of ePlex®: The True Sample-to-Answer Solution™ to Improve the Quality of Patient Care
Supported by GenMark Diagnostics 
Location: Westin, Harbor Ballroom B

The clinical utility of novel Aptima assays on Panther: HCV viral load monitoring and detection of Zika virus infection
Supported by Hologic 
Location: Westin, Grand Ballroom Salon A

pcr.ai (formerly known as Azure PCR’s AccuCall) presents a workshop on qPCR and artificial intelligence 
Supported by pcr.ai (formerly known as Azure PCR’s AccuCall) 
Location: Westin, Grand Ballroom Salon D

In it for Life:  The Importance of Continuity of Care for HIV-1 Infected Patients 
Supported by Roche Diagnostics 
Location: Savannah International Trade & Convention Center, Room 105/106

HIV and HCV Sequencing: Practical Approaches for Sanger and NGS, enabled by SmartGene’s Modules
Supported by SmartGene 
Location: Westin, Grand Ballroom Salon E/F

 



Monday, May 8, 2017 - 
1:15 p.m. – 2:45 p.m.

Performance evaluation of the Abbott RealTime CMV* assay on the m2000 platform
Supported by Abbott Molecular
Location: Westin, Grand Ballroom Salon C

Speaker:
Performance evaluation of the Abbott RealTime CMV* assay on the m2000 platform 
Melinda D. Poulter, Ph.D., D (ABMM) 

Overview:
Dr. Poulter will provide an overview of the experience her laboratory has observed with Abbott’s RealTime CMV* assay. She will review analytical performance characteristics such as linearity and inter-run precision; and present data on patient correlation between her test of record- Roche CAP/CTM, and the Abbott RealTime CMV assay. *Not commercially available in the US.

 

Elevating the Standard of Care for Diagnosis and Management of Vaginitis & Vaginosi 
Supported by BD Diagnostics 
Location: Savannah International Trade & Convention Center, Room 203-205

Speaker:  
Kimberle C. Chapin, MD (ABMM); FCAP Lifespan Academic Medical Centers & Brown Medical School, Director of Microbiology & Professor of Pathology and Medicine

Overview:
Vaginal infections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and trichomoniasis (TV), are among the most common reasons for which women in the United States seek medical care. Approximately 30% of symptomatic women remain undiagnosed or misdiagnosed after clinical evaluation. In addition, many symptomatic women assume they have a simple yeast infection and attempt to self-treat with over-the-counter antifungals. However, patients incorrectly self-diagnose over 50% of the time. Current methods for diagnosis of these conditions lack both sensitivity and specificity and result in high patient dissatisfaction and incorrect treatment, potential for continued transmission of TV, and significant costs to the healthcare system.

 

Big Changes in Influenza Testing, Are you Ready?
Supported by Cepheid
Location: Savannah International Trade & Convention Center, Oglethorpe Auditorium

Moderator:
Ellen Jo Baron, Ph.D; Executive Director of Medical Affairs at Cepheid

Speakers:
Raquel Martinez, Ph.D; Associate Director, Clinical Microbiology at Geisinger Medical Laboratories
Jesse Papenburg, MD; Pediatric Infectious Disease Specialist and Medical microbiologist at Montreal Children’s Hospital, McGill University Health Centre
Daniel A. Green, MD; Assistant Professor of Pathology and Cell Biology, Assistant Director of Clinical Microbiology at New York Presbyterian Hospital, Columbia University Medical Center

Overview:
Learn about improved respiratory testing algorithms and rapid PCR tests in light of the FDA’s recent reclassification of immunoassay based influenza testing.

 

ELITe InGenius®, the Highly Flexible Sample-to-Result Solution 
Supported by ELITechGroup Molecular Diagnostics 
Location: Westin, Grand Ballroom Salon B

Speakers:
Validation of the ELITe InGenius® System for transplant pathogen monitoring in a lean laboratory 
Phillip Ruiz, MD, PhD, F.A.S.T.; Medical Director, Immune, Monitoring Laboratory, University of Miami Miller School of Medicine

ELITe InGenius® an innovative sample-to-result solution for the detection of not-so-common respiratory pathogens: pneumocystis and legionella 
Scott McClellan, BS, MT (ASCP); Chief Technologist, Molecular Infectious Disease R&D, Michigan Medicine

Evaluation of multiple BKV standards panels on ELITe InGenius® sample-to-result system 
David Hillyard, MD; Medical Director, Molecular Infectious Diseases, ARUP

Overview:
The ELITe InGenius system is an open, integrated and easy-to-use sample-to-result solution. ELITe InGenius automatically performs nucleic acid extraction, quantitative PCR, and results interpretation on one single platform with unprecedented flexibility and efficiency, enabling laboratories to run parameters according to their specific needs. ELITe InGenius enables laboratories to streamline workflow, reduce hands-on time and limit the risk of errors while ensuring high-performance results. 

The ELITechGroup workshop will include lectures from distinguished speakers describing their laboratory experience using the ELITe InGenius® system and its breakthrough performance. 

  • Phillip Ruiz, Medical Director in the Immune Monitoring Laboratory at the University of Miami, will describe and analyze the workflow impact of ELITe InGenius routine use, in a high throughput lean laboratory for Transplant Pathogen Monitoring, in comparison to conventional PCR workflow.
  • Scott McClellan, Chief Technologist at Michigan Medicine, will discuss the benefits of ELITe InGenius use considering the performance and workflow improvements for respiratory pathogens testing: legionella and pneumocystis.
  • David Hillyard, Medical Director at ARUP Laboratories, will present the result of multiple BKV standards panels evaluation performed with ELITe InGenius, demonstrating the high-performance and reproducibility of the system for quantitative applications.

 

Panther Fusion and a Novel Approach to Syndromic Respiratory Testing 
Supported by Hologic, Inc
Location: Westin, Grand Ballroom Salon A

Speakers:
Detection and Identification of Respiratory Viruses - A Review
Rangaraj Selvarangan, BVSc, PhD, D(ABMM); Director of Clinical Microbiology, Virology and Molecular Infectious Diseases Laboratory, Children’s Mercy Kansas City

Comparative Evaluation of the Panther Fusion Flu A/B/RSV, Paraflu, AdV/hMPV/RV Assays to two syndromic multiplex respiratory assays in a Multi-Hospital Health Care Setting 
Stefan Juretschko, PhD, D(ABMM); Senior Director for Division of Infectious Disease Diagnostics, Northwell Health Laboratories

Overview:
Respiratory viral infections remain a leading cause of infectious diseases worldwide. Because most respiratory viruses present with similar symptoms, molecular diagnostic tools are required for rapid and accurate diagnosis to ensure appropriate patient management. Current diagnostic techniques include insensitive rapid tests, costly mega-panels, or complicated work-flow involving multiple assays. The Panther Fusion™ system and respiratory panels (in development) address the clinical need for a flexible, modular approach to syndromic testing. The Panther Fusion Respiratory panels are qualitative multiplex RT-PCR assays which detect and differentiate multiple targets utilizing assay specific reaction mixtures. Panther Fusion offers random access capability, minimum sample handling, and short sample in-to-first result processing to identify Influenza A and B (Flu A/B), Respiratory Syncytial Virus (RSV), Parainfluenza virus 1, 2, 3, 4 (Paraflu), Adenovirus (AdV), human Metapneumovirus (hMPV), and Rhinovirus (RV). The three respiratory panels can be run from a single nasopharyngeal swab (NP) or LRT specimen (bronchoalveolar lavages, BAL; bronchial washes, BW). This symposium describes a preliminary performance and workflow analysis of the Panther Fusion Respiratory assays compared to two syndromic multiplex respiratory panels. Dr. Selvarangan will present an overview of the epidemiology of respiratory viruses, as well as a synopsis of the currently available traditional and molecular based technologies for their detection and identification. This will include a detailed discussion of the clinical impact of multiplexed respiratory viral PCR assays. Dr. Juretschko will give a short introduction to the newly developed Panther Fusion instrument, followed by a pre-market data analysis, comparing the Panther Fusion Flu A/B/RSV, Paraflu, AdV/hMPV/ RV respiratory assays to two large syndromic panels, the BioFire FilmArray Respiratory Panel and Luminex NxTag Respiratory Viral Panel. Assay performances with focus on sensitivity, specificity, and workflow analysis will be discussed in detail. In addition, Dr. Juretschko will highlight the possible fit of these respiratory virus assays in a 22-Hospital Health Care system.

 

Flexible Solutions from Luminex – The Right Test for Your Lab
Supported by Luminex Corporation
Location: Westin, Grand Ballroom Salon E/F

Speakers: 
VERIGENE® RP Flex assay
Yvette S. McCarter, PhD, D(ABMM) Professor; Department of Pathology & Laboratory Medicine; Director, Microbiology Laboratory at UF Health Jacksonville UF Health

NxTAG® RPP assay
Lech Mazur, MS MLS(ASCP); Technical Director, Molecular Pathology lab from ACL

Overview: 
We will begin by addressing the diagnostic challenges faced by physicians and laboratories and how molecular solutions from Luminex can help labs meet those challenges to provide reliable, timely, and actionable answers. We’ll also further discuss recent updates on the ARIES® Systems — Luminex’s sample to answer real time PCR platform, and the latest additions to the ARIES® IVD menu.

  • Yvette S. McCarter, PhD, D(ABMM) from UF Health Jacksonville will share her experience with the VERIGENE® RP Flex assay and why it is the perfect solution for her laboratory’s respiratory testing needs.
  • Lech Mazur, MS MLS(ASCP), Technical Director, Molecular Pathology lab from ACL will present his work with the NxTAG® RPP assay and describe the benefits of the NxTAG RPP assay when managing a high volume laboratory.


VZV: The Great Imposter / CDC Guidelines for Influenza Testing and Impact on Algorithms
Supported by Quidel Corporation
Location: Westin, Harbor Ballroom B

Speakers:
VZV: The Great Imposter
Paul A. Granato, Ph.D., DABMM, FAAM; Professor Emeritus of Pathology, SUNY Update Medical University and Director of Microbiology Laboratory Alliance of Central New York

Influenza: CDC Guidelines and Efficient Management
Suzane Silbert, Ph.D.; Molecular-Clinical Scientist, Esoteric Testing Lab/Pathology Department Studies, Tampa General Hospital
Ray Widen, Ph.D.; Scientific Director, Esoteric Testing/R&D, Tampa General Hospital

 

The Odyssey of Disparities in Standardizing CMV Viral Load Testing:  Have the Seas Subsided? 
Supported by Roche Diagnostics
Location: Savannah International Trade & Convention Center, Room 105/106

Speakers:
Alex Valsamakis, MD, PhD; Director, Clinical Virology and Molecular Microbiology, & Associate Professor of Pathology, The Johns Hopkins University School of Medicine

Neelam Dhiman, PhD; Scientific Director, Molecular Infectious Diseases, med fusion and ClearPoint Diagnostics Labs & Clinical Associate Professor, Department of Pathology and Laboratory Medicine, Texas A&M University

 

RTT MOLECULAR DIAGNOSTICS WORKSHOP
Supported by RTT Molecular Diagnostics
Location: Westin, Harbor Ballroom A

Speaker:
Hepatitis C Virus (HCV) and the Important Role of Drug Resistance Diagnostics in the New Era of Direct Acting Antivirals (DAA)

A Comparison of HIV-1 and Hepatitis C - A History Remembered

Dr. Robert M. Lloyd, Jr.; Chief Scientific Officer RTTMDx. Dr. Robert M. Lloyd Jr., is a noted pioneer and thought leader in infectious disease drug resistance genotyping diagnostics.  Mr. Lloyd is credited with being co-discover of lamivudine (3TC) drug resistance and an inventor of the first FDA cleared drug resistance genotyping test, TRUGENE® HIV-1 Drug Resistance Genotyping Kit.  Mr. Lloyd has served as principle investigator for many FDA diagnostic products and NDA clinical trials for HIV-1, HBV, CMV, and HCV.  Mr Lloyds experience includes owning-operating a CLIA approved reference laboratory, performing novel laboratory tests for clinical trials, collaborations, and Pharmaceutical partnerships and alliances.

Overview:
Recent FDA drug approvals rely on surrogate molecular testing inclusive of commercial diagnostic test for Viral Load and “TYPING” and more recently FDA product insert with guidance recommendation for Drug Resistance (DR) testing. Historically, "Typing” test are a carry over from the Indirect Acting (IA) Interferon based therapeutics studies. These commercial typing results are somewhat misleading and inaccurate in that they do not address recombinant populations nor specific define DAA compounds responders because of Type generalizations and subsequent "drug labeling” for use.

 

Monday, May 8, 20173:00 p.m. – 4:30 p.m.

The FilmArray® Respiratory Panel 2 (RP2) Advancing the Syndromic Approach: Faster, More Accurate, More Comprehensive…Than Ever!
Supported by BioFire Diagnostics
Location: Westin, Grand Ballroom Salon C

Speakers:
Clinical Trial Results for the FilmArray RP2
Judy Daly, Ph.D.; Professor of Pathology, University of Utah; Director–Microbiology Laboratories, Primary Children’s Medical Center, Salt Lake City, Utah

Adoption and Use of the FilmArray® Torch System
Susan Whittier, Ph.D. ABBM; Assoc. Professor of Clinical Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York

Overview:
Come and learn about the next-generation respiratory panel from BioFire Diagnostics as we introduce the FilmArray® Respiratory Panel 2 (RP2). The FilmArray® RP2 provides faster, more accurate, more comprehensive test results than ever to aid clinicians in formulating better informed diagnoses and treatment decisions for their patients suffering from respiratory illness.


Lyophilizing PCR Master Mixes for Molecular Diagnostic Assays
Supported by BIOLYPH
Location: Westin, Harbor Ballroom A

Speaker: 
Lyophilizing PCR Master Mixes for Molecular Diagnostic Assays
Timothy Pearcy; Founder and Managing Director of BIOLYPH
    
Overview: 
BIOLYPH provides PCR Master Mix lyophilization services for molecular diagnostic assay developers & manufacturers.

A single Master Mix LyoSphere™ can contain Enzymes, Oligonucleotides, Dyes, RNAse Inhibitors, Cations, dNTPs, Buffers and Excipients in a stable, consistent form, which rehydrates instantly and can be packaged into virtually any device format.

Featuring Timothy Pearcy, Founder and Managing Director of BIOLYPH, learn about BIOLYPH’s capabilities to provide lyophilized PCR Master Mixes for molecular diagnostic assays that yield the benefits of simplified product storage and transport, higher product stability over broader temperature tolerances, longer product shelf-life, and superior end-user ease of use.

 

Advances in Lab Detection of C. difficile and Group A Strep 
Supported by DiaSorin Molecular
Location: Westin, Grand Ballroom Salon B

Speaker:
Integration of the Simplexa® C. difficile Direct Assay in a two-step algorithm for the laboratory diagnosis of C. difficile
James W. Snyder, Ph.D. (ABMM), F(AAM); Director, Microbiology and Molecular Diagnostics, University of Louisville School of Medicine Division of Laboratory Medicine

Overview:
Clostridium difficile is a major pathogen responsible for infectious diarrhea in healthcare settings. US Clostridium difficile infection (CDI) has an estimated cost ranging from $500 million to $1.5 billion per year. In an effort to reduce healthcare costs including reduced length of hospital stays related to CDI, the clinical microbiology laboratories are challenged and pressured to provide rapid, accurate, and cost-effective test results.

This presentation will review the data from a study comparing the new Simplexa® C. difficile Direct assay with our in-house two-step algorithm and two additional PCR-based assays (Great Basin, GeneXpert Infinity) in which PCR was utilized as a confirmatory rather than a direct assay.

Speaker:
Conversion of Group A Streptococcus Confirmation Testing from Culture to Molecular: Automation, Workflow Improvements and Antimicrobial Stewardship
Donna M. Wolk, MHA, Ph.D., D(ABMM); System Director, Clinical and Molecular Microbiology, Geisinger Health System, Department of Laboratory Medicine

Overview: 
Streptococcus pyogenes or Group A Streptococcus (GAS) is a pathogenic bacteria that causes both invasive and non-invasive infections resulting in mild to severe life-threatening disease. The non-invasive infections generally include infections of the skin, as well as pharyngitis and tonsillitis, more commonly known as strep throat. Pharyngitis and tonsillitis are a significant health issue for all ages, however, the vast majority of cases are found in children. It is estimated that nearly 7.3 million children are seen as out-patients for streptococcal pharyngitis in the U.S. alone every year.

Although direct streptococcal antigen assays offer rapid results, they are less accurate than culture. Laboratory guidelines mandate that a more sensitive confirmatory test is performed on negative rapid antigen samples. However, routine culture detection of the organism can take an additional 24-48 hours. As an alternative, rapid molecular testing for Group A Strep can offer a faster and more efficient method for confirmation, contributing to the accelerated treatment of the patient.

During this presentation you will learn how our laboratory implemented a rapid, automated high-throughput method for molecular confirmation of rapid antigen negatives. The advantages of moving this assay from culture to molecular in terms of workflow and increased sensitivity will be discussed. Population health and antimicrobial stewardship will also be discussed.

 

Implementation of ePlex®: The True Sample-to-Answer Solution™ to Improve the Quality of Patient Care
Supported by GenMark Diagnostics
Location: Westin, Harbor Ballroom B

Speakers:
Performance of the ePlex Respiratory Pathogen Panel in Comparison to Lab Developed Tests and the Utility in Clinical Practice
Roel Nijhuis, Ph.D. Medical Molecular Microbiologist, Department of Medical Microbiology, Leiden University Medical Center

Strategic Planning for Implementation of Novel Diagnostics
Kimberle Chapin, M.D. (ABMM, FCAP) Professor of Pathology and Laboratory Medicine and of Medicine at Warren Alpert School of Medicine at Brown University; Director of Microbiology for Lifespan Academic Medical Center

Overview:
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. In this workshop, you will learn about strategies throughout the hospital for implementing the ePlex Respiratory Pathogen Panel and assessing test performance for both workflow and clinical impact on patient care.

 

The clinical utility of novel Aptima assays on Panther: HCV viral load monitoring and detection of Zika virus infection
Supported by Hologic
Location: Westin, Grand Ballroom Salon A

Speakers:
Clinical evaluation of the new Aptima HCV Quant Dx Real-time TMA Assay
Belinda Yen-Lieberman, Ph.D.

Zika virus: epidemiology, clinical features, and laboratory diagnosis
Michael Loeffelholz, Ph.D., D(ABMM)

Overview: 
Transcription mediated amplification (TMA) is a well-known technique that demonstrates high sensitivity and specificity for targets in a variety of disease states. This presentation will highlight the clinical utility of two new TMA assays available on the Panther system: Aptima HCV Quant Dx Assay (US-IVD: diagnosis and monitoring) and Aptima Zika Virus Assay (EUA). Hepatitis C and Zika virus are both members of the virus family flaviviridae that utilize a single-stranded RNA genome. Accurate diagnosis and monitoring of these infections is of global importance to prevent transmission and to link patients into treatment.

 

pcr.ai (formerly known as Azure PCR’s AccuCall) presents a workshop on qPCR and artificial intelligence 
Supported by pcr.ai (formerly known as Azure PCR’s AccuCall) 
Location: Westin, Grand Ballroom Salon D

Speaker: 
pcr.ai in depth demo: From qPCR amplification to the LIMs in 5 minutes. 
Aron Cohen; CEO, pcr.ai

pcr.ai case study: Analysing 350,000 results in a day. Beat the machine: including prizes for the winner.
 
Aron Cohen; CEO, pcr.ai

Overview:  
Artificial intelligence (AI) can make your qPCR testing cheaper, quicker and safer. This is the focus of pcr. ai (aka Azure PCR’s AccuCall) and we are excited to present a workshop on our innovative diagnostic AI tool. pcr.ai automates and standardises your qPCR curve analysis and interpretation, works with all cyclers and provides over 99.9% interpretation accuracy (shown in 6 independent studies with over 0.25m samples). Our unmissable workshop includes: 

  • pcr.ai in depth demo: From qPCR amplification to the LIMS in 5 minutes.
  • pcr.ai case study: Analysing 350,000 results in a day.
  • Beat the machine: Can you beat pcr.ai at curve analysis?
  • Refreshments.
  • Stay ahead of the curve with pcr.ai, the future of diagnostic technology.

In it for Life:  The Importance of Continuity of Care for HIV-1 Infected Patients 
Supported by Roche Diagnostics
Location: Savannah International Trade & Convention Center, Room 105/106

Speakers: 
William Valenti, MD; Senior Vice President for Organizational Advancement, Co-Founder, & Staff Physician, Trillium Health

Denise Heaney, PhD; Molecular Clinical Specialist, Roche Diagnostics

HIV and HCV Sequencing: Practical Approaches for Sanger and NGS, enabled by SmartGene’s Modules
Supported by SmartGene
Location: Westin, Grand Ballroom Salon E/F

Speaker: 
Glen Hansen, PhD; Director of Clinical Microbiology and Molecular Diagnostics at Hennepin County Medical Center, Minneapolis, MN and Associate Professor in the departments of Laboratory Medicine & Pathology and the Department of Medicine (infectious disease) at the University of Minnesota.

Overview: 
Clinical virology continues to be at the forefront of diagnostic sequencing. Sanger-based methods remain very relevant for routine testing purposes; Next Generation Sequencing (NGS) platforms present significant laboratory, bio-informatics and regulatory challenges to be addressed, if adoption is to occur for routine use. In this workshop, Glen Hansen PhD (University of Minnesota and Hennepin County Medical Center) will present his laboratory’s practical experience designing and implementing a Sanger-based assay for HIV genotyping and resistance assessment. He will explain why and how this test method was implemented and how SmartGene’s software module for data analysis facilitates their routine process. Thereafter, a representative of SmartGene will provide an overview of SmartGene’s solutions for NGS data analysis, interpretation and reporting, showing how SmartGene provides bridging technologies to ensure continuity of valuable genetic data over time.

 

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH

94930